More notably, our previous integrated proteomics-based analysis of serum PON1 utilizing a wide-range of patient serum samples diagnosed with different LC sub-types indicated that the PTM glycosylation of PON1 in form of fucosylated PON1 is a highly specific biomarker for the diagnosis of SCLC [13]. Here, PON1 is linked to small cell lung carcinoma.